Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.41 |
| ▸ | PGR | P06401 | 8/20 | 0.41 |
| ▸ | AR | P10275 | 5/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21143398 | 1.00 | NR3C1 (0.41) | NR3C1PGRARCYP2C8SRD5A2 | |
| SCHEMBL23131219 | 1.00 | NR3C1 (0.41) | NR3C1PGRARCYP2C8SRD5A2 | |
| SCHEMBL4976232 | 0.82 | SRD5A2 (0.43) | SRD5A2CYP19A1 | |
| SCHEMBL13361969 | 0.82 | SRD5A2 (0.43) | SRD5A2CYP19A1 | |
| SCHEMBL4976238 | 0.82 | SRD5A2 (0.43) | SRD5A2CYP19A1 | |
| SCHEMBL9359021 | 0.82 | SRD5A2 (0.43) | SRD5A2CYP19A1 | |
| SCHEMBL9471996 | 0.82 | KDM4E (0.36) | PGRARCYP19A1 | |
| SCHEMBL9171069 | 0.82 | KDM4E (0.36) | PGRARCYP19A1 | |
| SCHEMBL11872466 | 0.82 | CYP19A1 (0.40) | SRD5A2CYP19A1 | |
| SCHEMBL8409113 | 0.80 | SRD5A2 (0.39) | NR3C1PGRARCYP2C8SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230096870-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-3851444-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | Oric Pharmaceuticals, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3523315-B1 | INHIBITOR OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20210017219-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-10836789-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10723759-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200055892-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-10472387-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472387-B2 | Inhibitors of glucocorticoid receptor | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
| US-20210017219-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
| US-20200055892-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
| US-10836789-B2 | Inhibitors of glucocorticoid receptor | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
| US-10723759-B2 | Inhibitors of glucocorticoid receptor | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
| US-20230096870-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.